Who is sponsoring NCT04414813?

NCT04414813 is sponsored by Shanghai East Hospital.

What drugs are being tested in NCT04414813?

Interventions in NCT04414813: Human Amniotic Epithelial Stem Cells.

What condition does NCT04414813 study?

NCT04414813 studies Parkinson's Disease.

Is NCT04414813 still recruiting?

NCT04414813 is currently completed. Last updated 12 April 2023.

Last reviewed 2023-04-12 · How we verify

NCT04414813

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Stereotactic Transplantation of hAESCs for Parkinson's Disease

Completed EARLY_PHASE1 Last updated 12 April 2023

What this trial tests

EARLY_PHASE1 trial testing Human Amniotic Epithelial Stem Cells in Parkinson's Disease in 3 participants. Completed in 8 February 2023.

Timeline

8 October 2020

Primary endpoint
8 February 2023

8 February 2023

Quick facts

Lead sponsor	Shanghai East Hospital
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	3
Start date	8 October 2020
Primary completion	8 February 2023
Estimated completion	8 February 2023
Sites	1 location across China

Drugs / interventions tested

Human Amniotic Epithelial Stem Cells — full drug profile →

Conditions studied

Parkinson's Disease — all drugs for Parkinson's Disease →

Sponsor

Shanghai East Hospital

Who can join

Adults 30 to 70, any sex, with Parkinson's Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and efficacy of stereotactic transplantation of hAESCs for Parkinson's disease.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Characteristics and Therapeutic Potential of Human Amnion-Derived Stem Cells.
Liu QW, Huang QM, Wu HY, Zuo GS, et al · · 2021 · cited 77× · PMID 33478081 · DOI 10.3390/ijms22020970
Stem Cell-Based Therapies for Parkinson Disease.
Liu Z, Cheung HH. · · 2020 · cited 55× · PMID 33137927 · DOI 10.3390/ijms21218060
Human Amniotic Epithelial Stem Cells: A Promising Seed Cell for Clinical Applications.
Qiu C, Ge Z, Cui W, Yu L, et al · · 2020 · cited 50× · PMID 33086620 · DOI 10.3390/ijms21207730
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update.
McFarthing K, Buff S, Rafaloff G, Pitzer K, et al · · 2024 · cited 49× · PMID 39031388 · DOI 10.3233/jpd-240272
The Use of Stem Cells as a Potential Treatment Method for Selected Neurodegenerative Diseases: Review.
Cecerska-Heryć E, Pękała M, Serwin N, Gliźniewicz M, et al · · 2023 · cited 39× · PMID 37027074 · DOI 10.1007/s10571-023-01344-6
Stem Cells: Innovative Therapeutic Options for Neurodegenerative Diseases?
Bonaventura G, Munafò A, Bellanca CM, La Cognata V, et al · · 2021 · cited 25× · PMID 34440761 · DOI 10.3390/cells10081992
Amniotic fluid characteristics and its application in stem cell therapy: A review.
Shamsnajafabadi H, Soheili ZS. · · 2022 · cited 20× · PMID 36313262 · DOI 10.18502/ijrm.v20i8.11752
Neural Cells for Neurodegenerative Diseases in Clinical Trials.
Fan Y, Goh ELK, Chan JKY. · · 2023 · cited 17× · PMID 37487111 · DOI 10.1093/stcltm/szad041

Verify or expand the search:

Other recruiting trials for Parkinson's Disease

Currently open trials in the same condition.

NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07330258 — A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite · recruiting
NCT07384429 — Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease · Phase 4 · recruiting
NCT07384442 — Effects of Targeted Temporal Interference Stimulation of Cerebellar Nuclei on Tremor and Gait Disturbance in Parkinson's · NA · recruiting
NCT06562569 — Non-invasive VNS for PD Gait · NA · recruiting

Other Shanghai East Hospital trials

Trials by the same sponsor.

NCT07519161 — Pharmacological Intervention to Prevent NOAF After TAVR · NA · not yet recruiting
NCT07516223 — MRI-Assisted Guidance for Non-Essential Tissue Sampling · NA · not yet recruiting
NCT07279259 — Thrombolysis in Early Acute Ischemic Stroke Trial-Blood Pressure Management · Phase 2 · recruiting
NCT07294495 — Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Tr · NA · not yet recruiting
NCT07290816 — Effect of Non-invasive Neuromodulation on the Quality of Intestinal Cleansing · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04414813 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai East Hospital
Last refreshed: 12 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04414813.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing